Navigation Links
Vista Partners Updates Coverage on Pro-Pharmaceuticals, Inc.; Raises Target Price to $3.22

SAN FRANCISCO, April 5, 2011 /PRNewswire/ -- Vista Partners announced today that it has updated coverage on Pro-Pharmaceuticals, Inc. (OTCBB: PRWP) ("the Company") and raised its twelve month target price to $3.22. Ross Silver, Principal Analyst at Vista Partners stated, "The Company stated that it has reached an agreement with the FDA on the design of a pivotal, randomized, controlled, and blinded Phase III clinical trial of DAVANAT®. We believe this to be a significant milestone in the Company's history and could open the door for a potential partnership." Mr. Silver continued, "The Company has stated that it plans to initiate a Phase I/ll clinical trial of DAVANAT® in combination with a melanoma vaccine in collaboration with the Ludwig Institute in Brussels, Belgium in the third quarter.  This collaboration to date has shown that DAVANAT® activates tumor-specific cytotoxic T-cells allowing them to kill tumor cells. In addition, the Company plans to obtain an IND for treatment of liver fibrosis in the fourth quarter and plans to initiate clinical trials in early 2012."  Mr. Silver concludes, "We believe Pro-Pharmaceuticals to be one of the most attractive small cap biotechnology companies we have come across as a result of its robust clinical pipeline, which includes two candidates entering the clinic later this year and a late stage clinical candidate for metastatic colorectal cancer, all of which would compete in multi-billion dollar markets if approved. In addition, the Company has a strong management team, which is led by CEO Dr. Peter Traber, the former Chief Medical Officer of GlaxoSmithKline plc."

To download a FREE copy of the Pro-Pharmaceuticals, Inc. research report, please visit and click the "download research" icon to gain access to the report.

About Vista Partners:

Vista Partners LLC was founded in 2005 and has offices in California and one in Oregon. Vista Partners LLC is a Registered Investment Advisor in the States of California and Oregon. The firm's professional staff has backgrounds in finance, corporate communications and investment banking. Vista Partners LLC has built a name for itself in the small cap space due to its selection of profitable investment ideas.

Disclaimer & Disclosure:

For a full list of disclaimers and disclosures, please visit our website or click here.

877.215.4813 or

SOURCE Vista Partners
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Harris Corporation Awarded Contract to Provide Engineering and Enterprise Support to Veteran Affairss VistA Imaging System
2. Anthera Announces Conference Call to Discuss Analytical Method and Timing of Upcoming VISTA-16 Biomarker Analysis
3. Vista Partners Updates Coverage on Pro-Pharmaceuticals, Inc.; Maintains Target Price of $2.10
4. New FORTEO® and EVISTA® Data to be Presented at Premiere Scientific Meeting for Bone and Mineral Research
5. Vista Partners Updates Coverage on Raptor Pharmaceutical Corp.
6. U.S. Court of Appeals Upholds Validity of Lillys Evista Patents Through March of 2014
7. Chula Vistas Dr. Peter Rullan Adds Alma Lasers Pixel CO2 Laser System to Offer Fractional CO2 Laser Treatments to Patients
8. Biovista Announces the Appointment of Clifford H. Farrah to its Advisory Board
9. New High-Resolution Computer Tomography Data Demonstrates EVISTA(R)s Effect on Bone Quality in Osteoporotic Patients
10. Watson Confirms EVISTA(R) Patent Challenge
11. Biovista Inc. and FDA to Collaborate on a Medication Safety Initiative
Post Your Comments:
(Date:12/1/2015)... VERONA, Va. , Dec. 1, 2015 /PRNewswire/ ... today unveiled a new corporate logo and brand ... in the design and engineering of bladed products ... --> --> Serving ... fiber, glass, and auto glass equipment, AccuTEC,s product ...
(Date:12/1/2015)... --> --> ... Acid Labeling Market by Product (Reagents & Kits, Services), ... Vitro Transcription, Reverse Transcription, End Labeling), by Region - ... market is expected to reach USD 1,925.7 Million by ... a CAGR of 8.65%. Browse 77 market ...
(Date:12/1/2015)... December 1, 2015 Russia has ... trials. 70% of new drugs registered in Europe ... . --> Russia has always been a ... new drugs registered in Europe in 2015 were ... Russia has always been a country of ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... ... continue the expansion of the company’s growing product line of food safety and ... tshawytscha) and Sockeye (Oncorhynchus nerka) – allow InstantLabs to offer fast, reliable species ...
(Date:12/1/2015)... ... 2015 , ... It’s official: Tattoo taboo is a thing of the past. ... Millennials (a whopping one in three aged 18 to 25 is inked). As tattoos ... their ink. In fact, RealSelf , the world’s largest community for learning and ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... of adjunctive imaging is the focus of numerous abstracts accepted for presentation here, ... 4, 2015. Nine abstracts highlight the use of Volpara Solutions’ quantitative breast ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... Inc. (“Visage”), a wholly owned subsidiary of Pro Medicus Ltd. (ASX: PME), has ... the Radiological Society of North America (RSNA) 2015 annual meeting through December 3 ...
(Date:12/1/2015)... ... December 01, 2015 , ... McLean, VA., December ... a fixed price per sprint agile development contract to support the National Geospatial-Intelligence ... five years, provides software engineering, infrastructure, as well as operations and sustainment support ...
Breaking Medicine News(10 mins):